Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Recurrence 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hematologic Diseases 1

Interventions

Rituximab 4Cyclophosphamide 4Etoposide 3Dexamethasone 3ponatinib 2pomalidomide 2fludarabine 2Whole-Body Irradiation 2Vincristine 2Sirolimus 2Prednisone 2Platelet Transfusion 2Mycophenolic Acid 2Lenalidomide 2Ifosfamide 2Doxorubicin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2Alemtuzumab 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2ricolinostat 1pembrolizumab 1nilotinib 1ibrutinib 1fludarabine phosphate 1epratuzumab 1daratumumab 1dacetuzumab 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hematologic Diseases × TAS4464 × Clear all
NCT02978235 2024-09-05

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Taiho Oncology, Inc.

Phase 1 Terminated
11 enrolled
LymphoidPlasma cell

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡